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Objectives: To assess the cost-effectiveness of the SGLT2is empagliflozin 10mg 
and 25mg compared to other SGLT2is (canagliflozin 100mg and canagliflozin 
300mg) when administered as an add-on to MET+SU in patients with T2DM in 
the UK. MethOds: Long-term diabetes-related complications, QALYs, and costs 
were estimated for T2DM patients failing MET+SU. A micro-simulation model was 
developed based on the United Kingdom Prospective Diabetes Study (UKPDS68) and 
the Januvia Diabetes Economic (JADE) model. A network meta-analysis comparing 
efficacy and safety across SGLT2is was used to populate the model. Data gaps were 
completed with information derived from published sources, including previous 
cost-effectiveness models. Costs and QALYs were estimated over a patients’ lifetime 
from the UK National Health Service perspective. Results: Empagliflozin 10mg 
attained the highest QALYs (6.991, compared to 6.98 for canagliflozin 100mg, 6.978 
for empagliflozin 25mg and 6.976 for canagliflozin 300mg) due to slightly better 
HbA1c, SBP and weight control, and a small number of non-severe hypoglycae-
mias, compared to higher doses. Canagliflozin 300mg was the most costly strategy 
(£32,087, vs. £31,217 for canagliflozin 100mg, £31,409 for empagliflozin 10mg and 
£31,557 for empagliflozin 25mg). Therefore, empagliflozin 10mg dominated both 
canagliflozin 300mg and empagliflozin 25mg, and resulted in an incremental cost-
effectiveness ratio of £17,445 per QALY gained vs. canagliflozin 100mg. However, 
incremental QALY and cost differences were not significant based on 95% percentile 
confidence intervals. These results remained robust when sensitivity analyses were 
conducted, including utilities, adverse events, discontinuation, modelling of weight, 
impact of BMI, duration of effect, time horizon and discount rates. cOnclusiOns: 
Differences in QALYs and costs between SGLT2is as add-ons to MET+SU were minor. 
On average, empagliflozin 10mg resulted to be the most cost-effective option for 
T2DM patients failing MET+SU when commonly accepted thresholds in the UK 
were considered, with an incremental cost per QALY of £17,445 compared to cana-
gliflozin 100mg.
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Objectives: Diabetic Foot Syndrome (DFS) is a serious and common complica-
tion of diabetes, often leading to limb amputation and disability. Disability and 
productivity loss in patients with DFS can generate significant indirect costs and 
potentially significant economic consequences. The purpose of the study is to esti-
mate productivity loss and indirect costs associated with foot ulceration in patients 
with DFS. MethOds: We conducted a prospective survey in a population of DFS 
patients with foot ulceration. Loss of productivity was measured with a modified 
WPAI questionnaire. Indirect costs of both absenteeism and presenteeism were 
estimated using the human capital approach on the basis of the measure of gross 
value added per employee. Results: Nearly one third of respondents (32%) declared 
that foot ulceration was the direct reason why they abandoned their professional 
activity. 40% and 34% of respondents, respectively, were forced to limit or change 
their professional activity at some point in the past because of the foot ulceration. 
More than 40% of respondents who changed or limited their professional activity 
because of the foot ulceration experienced reduction in earnings by 22.9% on aver-
age. Mean absenteeism was estimated at 32.63% of the nominal working time, while 
presenteeism was estimated at 23.48% of real working time. Total annual indirect 
costs associated with productivity loss amounted to EUR 170.8 million, including 
EUR 117.3 million of the costs of sickness absence and EUR 53.5 million of the costs 
of presenteeism. cOnclusiOns: Foot ulceration in patients with DFS is a com-
mon cause why patients are forced to give up or change their professional activity, 
which usually leads to a reduction in earnings. Indirect costs associated with foot 
ulceration in DFS impose a significant burden on the Polish economy. There is no 
rationale that would clearly link productivity loss associated with ulceration in DFS 
and the ulceration severity.
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Objectives: Insulin administration in the acute care setting is an integral com-
ponent of inpatient diabetes management. The current method of administration 
in acute care settings is by vial and syringe. The aim of this study was to evalu-
ate the impact of insulin pen implementation in the acute care setting on patient 
and health care worker safety, and health resource utilization (HRU). MethOds: A 
review of published literature was conducted to identify how insulin pen devices 
in the acute care setting may impact inpatient diabetes management. Additionally, 
nurse researchers from the McGill University Health Centre conducted a pilot study 
in a 52-bed unit to quantify this impact in a local context. Together, the results of 
the literature search and the pilot served as the inputs to an economic model, 
developed in Excel v14. Costs for the volume of insulin dispensed, injection sup-
plies, needlestick injury management, and nursing labour were assessed. Results: 
Previous published studies have revealed that insulin pen devices have the poten-
tial to improve inpatient management through better glycemic control, increased 
adherence and improved self-management education. The combined results from 
the literature and pilot indicate that moving from vial and non-safety syringe to 
a passive safety pen in acute care results in total estimated annual cost savings 
of $43,339.66, and 191.42 hours of nursing time saved (site with 52 beds dedicated 
to patients with diabetes). Cost savings from the adoption of a passive safety 
insulin pen were predicted based on reductions in insulin volume and needle-
stick injuries. For an institution of similar size using safety syringes, the move to a 
the comparative efficacy and safety across SGLT2is. Data gaps were completed with 
information derived from published sources, including previous cost-effectiveness 
analyses. The UK National Health Service (NHS) perspective was considered to esti-
mate costs and QALYs over a patients’ lifetime. Results: There were small differ-
ences in efficacy and safety across SGLT2is, which resulted in minor QALY and cost 
differences across treatment combinations. On average, empagliflozin 25mg obtained 
incremental QALYs of 0.029 versus dapagliflozin 10mg and 0.019 versus canagliflozin 
100mg, and incremental costs of £178 and £86, respectively, whereas both canagli-
flozin 300mg and empagliflozin 10mg were dominated by empagliflozin 25mg. This 
resulted in an incremental cost-effectiveness ratio (ICER) of £4,858 per QALY gained 
with empagliflozin 25mg vs. canagliflozin 100mg. However, the differences across 
treatments were not significant when 95% percentile confidence intervals were 
considered. These results were robust to a number of sensitivity analyses including 
a 10-year time horizon, BMI impact, discount rates and parameter values related 
to utilities, disutilities, adverse events, and discontinuation rates. cOnclusiOns: 
Overall, differences in QALYs and costs were minor between SGLT2is used as add-on 
to metformin in UK T2DM patients. On average, empagliflozin 25mg was the most 
cost-effective strategy, with an ICER of £4,858 per QALY gained vs. canagliflozin 100mg.
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Objectives: A small, minimally-invasive flash glucose monitor (FGM) has recently 
been developed. Arm sensors worn up to 14 days interact with a hand-held reader 
to convey 8 hours of continuous glucose level data. The reader stores data, com-
municating glucose control via trend charts. Economic evaluation of FGM vs. con-
ventional blood glucose monitoring (BGM) has not been conducted. This analysis 
estimates potential cost-effectiveness of using FGM in UK insulin-treated type 2 
diabetes mellitus (T2DM) patients. MethOds: The IMS Core Diabetes Model (CDM) 
was used for analyses, assuming a lifetime horizon (40 years). Patient characteristics 
were based on early FGM feasibility trial data. Effectiveness was measured in life 
years (LY) and quality-adjusted life years (QALY), with assumptions around FGM 
effectiveness based on expected benefits of use. These include: a) lower HbA1c by 
0.35%-0.5% compared to BGM over the horizon; b) utility improvement due to fewer 
finger pricks of 0-0.03; c) minor hypoglycaemic event rate reduction of 0% or 50% 
compared to BGM due to potential improved glycaemic control. Cost data (direct 
costs only) were extracted from published literature and government sources, and 
inflated to 2013 GBP. Incremental cost-effectiveness ratios (ICERs) were estimated, 
and threshold analysis was performed to estimate potential total FGM sensor costs 
for each scenario. Results: Based on assumptions above, the ICER for FGM vs. 
BGM ranges from £10,034-£29,068/QALY. With 0.5% HbA1c improvement, 0.01 util-
ity benefit, and no difference in hypoglycaemic events, the ICER is £17,808/QALY. 
Assumptions around utility improvement have a larger ICER impact than HbA1c 
benefit or change in minor hypoglycaemic events. Threshold analysis shows that 
with a conventional ICER threshold (£30,000/QALY), £14,606-£27,956 can be spent on 
sensors over a lifetime across scenarios. cOnclusiOns: Using an alternate glucose 
monitoring method could be cost-effective across a variety of clinical benefit and 
cost assumptions in T2DM (T1DM analysis forthcoming).
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Objectives: To evaluate the cost-effectiveness of canagliflozin, an active inhibitor 
of sodium glucose co-transporter – 2 (SGLT2), in triple therapy of diabetes as add-
on to metformin and sulfonylurea compared to NPH insulin in combination with 
oral antidiabetics. Canagliflozin in clinical trial results showed effective glucose 
reduction, along with other benefits in diabetes treatment including weight loss 
and SBP reduction. Cost effectiveness analyses were conducted in the Polish set-
ting from a public perspective in accordance with guidelines of Polish HTA Agency 
(PolAHTA). MethOds: The IMS CORE Diabetes Model was used to evaluate the 
cost-effectiveness of canagliflozin in triple therapy versus NPH insulin using Polish-
specific data, where available. Clinical data were derived from mixed treatment 
comparison analysis of published studies, as there is no head to head trial com-
paring canagliflozin with NPH insulin. Direct costs were reported in Polish zloty 
and an annual discount rate of 5% and 3.5% were applied on costs and effects 
respectively. Results: In a triple therapy as add-on to metformin and sulfonylurea 
canagliflozin is a cost- effective treatment option in comparison with NPH insulin 
with ICERs of 4 477 z³ and 69 081 z³ for canagliflozin 100 mg and 300 mg respec-
tively. Associated QALY gains were 0,084 and 0,106. Both results are below defined 
in Polish reimbursement act cost-effectiveness threshold. cOnclusiOns: These 
results suggest that adding Canagliflozin to dual therapy versus insulin intensifica-
tion in patients inadequately controlled with MET+ SU would be a more efficient 
use of health care resources in the Polish setting.
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ER attendance, costs were calculated multiplying resource use by corresponding unit 
costs. Regarding hospitalization, length of stay was multiplied by daily cost obtained 
through hospitals accountancy. Both costs were summed and descriptive statistics 
were calculated. Productivity loss cost within ER admission and hospitalization was 
calculated for employed patients using the Human Capital Approach. Results: 238 
patients were enrolled and 105 (44%) were hospitalized. These patients had a median 
length of stay of 5.4 days and were most commonly hospitalized at the Internal 
Medicine department (n= 80; 76%). Nine patients (8.6%) died during hospitalization. 
Hospitalized patients had the following average (range) costs: pre-hospital care and 
transport € 34 (€ 0-€ 92); emergency room € 218 (€ 58-€ 1,348); hospitalization € 2,880 
(€ 140-€ 26,486); productivity loss costs due to ER and hospitalization € 31 (€ 0-€ 1,579). 
Thus, mean total cost per hypoglycemic event leading to hospitalization was € 3,163 
(€ 230-€ 26,818). cOnclusiOns: We conclude that severe hypoglycemia represent a 
substantial cost to Society and to the public hospitals of the National Health System 
in particular for those cases requiring hospitalization.
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Objectives: Hypoglycemia, which if left untreated, can be severe and result in sei-
zures, unconsciousness, and coma, during which another person’s help is required to 
administer a rescue dose of glucagon. Injectable glucagon kits are difficult to use and 
require training to administer. This study aimed to quantify the economic impact of 
using glucagon kits on resource use and costs, and identify evidentiary gaps requiring 
future research. MethOds: A conceptual model was developed illustrating the series 
of events resulting from a SHE: successful administration of glucagon, ambulance 
calls, transport to the ED, inpatient admission, and outpatient follow-up. A literature 
search was conducted to assess service use and costs associated with severe hypo-
glycemia events (SHE). English language articles were reviewed in PubMed, EMBASE 
and Cochrane databases. Results: Resource use associated with SHE, as a function 
of successful administration of glucagon, has not been systematically evaluated in the 
literature. Uncertainty exists for the probability of receiving a glucagon prescription 
for diabetics and successful use of glucagon kits. Furthermore, based on success-
ful administration of glucagon, the probability of ambulance calls, transports to the 
ED, inpatient admissions, and frequency of outpatient follow-up are lacking in the 
literature. cOnclusiOns: Diabetes is a costly condition for payers, and a common 
complication is hypoglycemia. Glucagon kits are effective in stabilizing diabetics’ 
blood glucose levels during SHE; however, oftentimes physicians do not prescribe, 
patients do not fill, or caregivers do not successfully administer glucagon due to 
the complex administration procedures. As less complicated glucagon products are 
developed, their value propositions must be informed by the economic implications 
resulting from the complex administration requirements of current kits. However, the 
current literature does not systematically evaluate these implications. Consequently, 
future research is needed to quantify the impact of non-successful administration of 
glucagon rescue kits, as well as the extent of under-utilization.
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Objectives: HIPOS-ER is an observational, cross-sectional, multicenter national 
study to describe the patient population of type 2 diabetics with hypoglycemic epi-
sodes that enter the emergency department caused by an anti-hyperglycemic agent 
(AHA). A key secondary objective is to estimate health care resource consumption 
and costs associated with this type of hypoglycemias. MethOds: The study was con-
ducted in 7 centers in mainland Portugal for a period of 12 months (Jan2013-Jan2014). 
Patient level data and resource utilization were collected. Average costs were assessed 
by multiplying 2014 unit costs (available from public sources) with all relevant health 
care resource consumption items registered in the emergency room following the 
hypoglycemia events and through hospital accountancy for the hospitalized patients 
(length of stay x daily mean cost of hospitalization). Results: The study enrolled 238 
patients and the calculated proportion of hypoglycemic episodes among all emer-
gency events in the same period was 0.075% (95%CI: 0.067%, 0.083%). In this popula-
tion, 55.0% of the patients were using insulin, 31.5% were treated with a secretagogue, 
6.7% were on a combination of insulin and a secretagogue oral agent and 6.7% were on 
oral non-secretagogue based AHA therapy. Mean patient age was 76 years and 57.6% 
were females. Estimated mean (range) of direct costs assessed in the emergency room 
were: emergency transportation € 33 (€ 0-€ 92), drugs € 4 (€ 0-€ 45), laboratory workup 56€ 
(€ 8-€ 212), other exams € 72 (€ 0-€ 944), physician and nurse time € 30 (€ 4-€ 211) and € 14 
(€ 1-€ 90), respectively. Mean hospitalization cost was € 1,271 (€ 0-€ 26,486). Mean indirect 
cost related with productivity loss within employed patients was € 15 (€ 0-€ 1,579). Total 
cost, including direct and indirect costs, was € 1,493 (€ 34-€ 26,818) per hypoglycemic 
event. Hospitalization was the main cost driver (85% of total costs). cOnclusiOns: 
We conclude that hypoglycemia represent a substantial cost for the Society and in 
particular for the public hospitals of the National Health System.
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passive safety pen device would result in total estimated cost savings of $17,865.40 
annually. cOnclusiOns: The implementation of insulin pen devices in acute care 
results in cost savings, as well as time savings for nurses that may be re-directed to 
increased time at the patient bedside.
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Objectives: The aim of this study was to assess the epidemiologic and economic 
burden of diabetic retinopathy (DR) in terms of incidence, treatment patterns 
and cost by a population-based study. MethOds: Eligible patients were identi-
fied through a data warehouse (DENALI), which matches demographic, clinical 
and economic data of about 9.9 million individuals of Lombardy region. The study 
population consists of all individuals with a diagnosis of diabetes who, during the 
period 1-1-2000 to 31-12-2010 received one of the following health care services: 
hospital admission (HA) for diabetes with ophthalmic manifestations or retinal 
disorders, fluorescein angiography or angioscopy of eye, destruction of chorioretinal 
lesion, repair of retinal tear, injection of vitreous substitute, and repeated oph-
thalmic examinations. The study population was followed for a minimum of 1 to 
a maximum of 10 years. We evaluated demographic characteristics of the study 
population and costs from the National Health Service’s perspective. Results: The 
2000-2010 DR population was estimated to be around 127,000 (52% male). The aver-
age incidence per year and the 2010-prevalence were 6.1 and 24.2 per 100 diabetic 
patients. Median age (min-max) at the index event was 68.6 (0.3-104.4) with 37% 
younger than 65-years. Around 15% of the population had Charlson Comorbidity 
Index> = 1 and the overall mortality was 41.8 deaths/100 patient-years. The 10-year 
mean cost for DR patients were 17,361€ (95%C.I. 12,673-22,050) compared with 4,771€ 
in a control diabetic population without complications. HA costs represented the 
driver of total costs, ranging from 45% (index year) to 36% (last year of follow-up), fol-
lowed by drug (30-34.4%) and outpatient (25-29.7%). During the index year 13% of HA 
and outpatient costs were attributed to eye-specialist departments. Approximately 
1% received intravitreal injections in 2010. cOnclusiOns: This study attempted 
to describe the burden of DR in Italy revealing socio-economic aspects relevant in 
terms of incidence and costs.
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Objectives: To evaluate the economic burden and health care utilization of patients 
diagnosed with hyperpotassemia in the U.S. Medicare population. MethOds: 
Hyperpotassemia patients (International Classification of Disease 9thRevision 
Clinical Modification ICD-9-CM diagnosis codes 276.7) were identified from the U.S. 
national Medicare claims from 01JAN2009 through 31DEC2011. The first diagnosis 
date was designated as the index date for the hyperpotassemia cohort. Patients 
without a hyperpotassemia diagnosis but of the same age, region, gender, index 
year and matched baseline Charlson Comorbidity Index score were identified for 
the comparison cohort, with a randomly-chosen index date to minimize selec-
tion bias. Patients were required to have continuous medical and pharmacy ben-
efits 1 year before and after the index date. Study outcomes (health care costs and 
utilizations) were compared between the disease and comparator cohorts using 
1: 1 propensity score matching (PSM). Results: A total of 90,528 patients were 
included in the hyperpotassemia and comparison cohorts. After 1: 1 PSM, 28,929 
patients were matched from each cohort, and baseline characteristics were pro-
portionate. Patients diagnosed with hyperpotassemia were more likely to utilize 
health care resources, including Medicare carrier (98.4% vs. 77.8%), Durable Medical 
Equipment (DME; 36.7% vs. 23.6%) and Home Health Agency (HHA; 18.4% vs. 7.3%) 
claims, outpatient visits (75.5% vs. 47.7%), inpatient (37.4% vs. 3.4%), skilled nursing 
facility (SNF, 13.3% vs. 3.4%) and hospice stays (1.1% vs. 0.8%) and prescription drug 
claims (54.1% vs. 50.7%). Patients diagnosed with hyperpotassemia also incurred 
higher Medicare carrier ($3,447 vs. $1,636), DME ($343 vs. $167), HHA ($938 vs. $412), 
outpatient ($11,006 vs. $4,534), inpatient ($7,156 vs. $1,463), SNF ($2,688 vs. $612), 
hospice ($244 vs. $198), pharmacy ($1,104 vs. $812) and total costs ($26,926 vs. $9,834) 
(p< 0.05). cOnclusiOns: The economic burden and health care resource utilization 
were significantly higher for patients diagnosed with hyperpotassemia.
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Objectives: HIPOS-ER is an observational, cross-sectional, multicenter study aimed 
(a) to describe type 2 diabetes patients treated with an anti-hyperglycemic agent 
(AHA) and admitted to the emergency room (ER) due to a hypoglycemic event and (b) 
to estimate health care resources use and its costs related with the ER hypoglycemic 
episode. In this analysis, costs within hospitalized patients following severe hypo-
glycemia assisted at the ER were specifically calculated. MethOds: The study was 
conducted in 7 centers in mainland Portugal for a period of 12 months (Jan 2013 – Jan 
2014). Costs related with these hospitalized patients were calculated considering the 
hospital perspective. Unit costs for 2014 were extracted from official sources and 
reported in euros. Patient level data were used to calculate average costs. Regarding 
